Cantor Fitzgerald analyst Charles Duncan reiterated a Buy rating on Aimmune Therapeutics (AIMT) today and set a price target of $64. The company’s shares opened today at $22.07, close to its 52-week low of $21.38.
Duncan commented:
“. We reiterate our Overweight rating and 12-month PT of $64/ share on AIMT. Aimmune announced today (BMO) that it initiated the international P3 POSEIDON (Peanut for Desensitization) study of AR101 in peanut allergic children 1–3 years of age. Enrollment criteria include a clinical history of peanut allergy, positive skin prick tests and/or elevated blood levels of peanut antibodies, and a double-blind, placebo- controlled food challenge (DBPCFC). Patients will undergo updosing for ~22 weeks to reach a dose of 300 mg per day of AR101/placebo and will continue a maintenance dose of 300mg for ~6 months. Primary endpoint for POSEIDON is similar to successful P3 PALISADE study – tolerating a 600mg dose of peanut protein.”
According to TipRanks.com, Duncan has currently no stars on a ranking scale of 0-5 stars, with an average return of -3.5% and a 39.4% success rate. Duncan covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, KalVista Pharmaceuticals Inc, and ACADIA Pharmaceuticals Inc.
Currently, the analyst consensus on Aimmune Therapeutics is a Moderate Buy with an average price target of $55.57, implying a 151.8% upside from current levels. In a report issued on December 12, Credit Suisse also maintained a Buy rating on the stock with a $40 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $42 and a one-year low of $21.38. Currently, Aimmune Therapeutics has an average volume of 611.7K.
Based on the recent corporate insider activity of 56 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA.
